SQZ Biotechnologies (SQZB) 10-Q 10 May 23 2023 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2023	May 04, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Entity Registrant Name	SQZ BIOTECHNOLOGIES COMPANY
Entity Central Index Key	0001604477
Entity Incorporation, State or Country Code	DE
Current Fiscal Year End Date	--12-31
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	SQZ
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		29,491,125
Entity Address, State or Province	MA
Entity File Number	001-39662
Entity Tax Identification Number	46-2431115
Entity Address, Address Line One	200 Arsenal Yards Blvd
Entity Address, Address Line Two	Suite 210
Entity Address, City or Town	Watertown
Entity Address, Postal Zip Code	02472
City Area Code	617
Local Phone Number	758-8672

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 39,872	$ 63,709
Prepaid expenses and other current assets	4,576	4,495
Total current assets	44,448	68,204
Property and equipment, net	1,810	1,959
Restricted cash	2,305	2,305
Operating lease right-of-use assets	24,594	27,432
Total assets	73,157	99,900
Current liabilities:
Accounts payable	2,485	2,511
Accrued expenses	4,871	8,893
Accrued restructuring expenses	468	3,162
Current portion of deferred revenue	678	715
Current portion of operating lease liabilities	4,188	6,562
Total current liabilities	12,690	21,843
Operating lease liabilities, net of current portion	20,311	20,909
Total liabilities	33,001	42,752
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized at March 31, 2023 and December 31, 2022; No shares issued or outstanding.
Common stock, $0.001 par value; 200,000,000 shares authorized at March 31, 2023 and December 31, 2022; 29,491,125 shares issued and outstanding at March 31, 2023 and December 31, 2022.	29	29
Additional paid-in capital	332,788	332,093
Accumulated deficit	(292,661)	(274,974)
Total stockholders’ equity	40,156	57,148
Total liabilities and stockholders’ equity	$ 73,157	$ 99,900

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	29,491,125	29,491,125
Common stock, shares outstanding	29,491,125	29,491,125

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Revenue		$ 2,869
Revenue, Product and Service [Extensible Enumeration]	us-gaap:ProductMember	us-gaap:ProductMember
Operating expenses:
Research and development	$ 12,976	$ 17,010
General and administrative	5,279	6,912
Total operating expenses	18,255	23,922
Loss from operations	(18,255)	(21,053)
Other income (expense):
Interest income	505	15
Other income (expense), net	63
Total other income, net	568	15
Net loss and comprehensive loss	$ (17,687)	$ (21,038)
Net loss per share, basic	$ (0.60)	$ (0.75)
Net loss per share, diluted	$ (0.60)	$ (0.75)
Weighted-average common shares outstanding, basic	29,491,125	28,145,036
Weighted-average common shares outstanding, diluted	29,491,125	28,145,036

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2021	$ 123,976	$ 28	$ 319,458	$ (195,510)
Beginning balance (Shares) at Dec. 31, 2021		28,133,368
Issuance of common stock upon exercise of stock options	29		29
Issuance of common stock upon exercise of stock options (Shares)		14,757
Stock-based compensation expense	1,947		1,947
Net loss	(21,038)			(21,038)
Ending balance at Mar. 31, 2022	104,914	$ 28	321,434	(216,548)
Ending balance (Shares) at Mar. 31, 2022		28,148,125
Beginning balance at Dec. 31, 2022	57,148	$ 29	332,093	(274,974)
Beginning balance (Shares) at Dec. 31, 2022		29,491,125
Stock-based compensation expense	695		695
Net loss	(17,687)			(17,687)
Ending balance at Mar. 31, 2023	$ 40,156	$ 29	$ 332,788	$ (292,661)
Ending balance (Shares) at Mar. 31, 2023		29,491,125

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net loss	$ (17,687)	$ (21,038)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization expense	214	276
Amortization of operating lease right-of-use assets	2,838	2,476
Stock-based compensation expense	695	1,947
Loss on disposal of equipment		41
Changes in operating assets and liabilities:
Accounts receivable		3,000
Prepaid expenses and other current assets	(81)	(881)
Accounts payable	(26)	(2,729)
Accrued expenses	(4,022)	1,716
Accrued restructuring expenses	(2,694)
Deferred revenue	(37)	(2,869)
Operating lease liabilities	(2,972)	(2,373)
Net cash used in operating activities	(23,772)	(20,434)
Cash flows from investing activities:
Purchases of property and equipment	(65)	(228)
Proceeds from disposals of property and equipment		34
Cash flows from investing activities	(65)	(194)
Cash flows from financing activities:
Proceeds from exercise of stock options		29
Net cash provided by financing activities		29
Net (decrease) increase in cash, cash equivalents and restricted cash	(23,837)	(20,599)
Cash, cash equivalents and restricted cash at beginning of period	66,014	145,818
Cash, cash equivalents and restricted cash at end of period	$ 42,177	$ 125,219

Nature of the Business and Basi

Nature of the Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of the Business and Basis of Presentation	1. Nature of the Business and Basis of Presentation SQZ Biotechnologies Company (the “Company”) is a clinical-stage biotechnology company developing cell therapies for patients with cancer and other serious medical conditions. The Company uses its proprietary technology, Cell Squeeze, to physically squeeze cells through a microfluidic chip, temporarily opening the cell membrane and enabling biologic material of interest, or cargo, to diffuse into the cell. The Company is using Cell Squeeze technology to create multiple cell therapy platforms focused on directing specific immune responses. The Company was incorporated in March 2013 under the laws of the State of Delaware. The Company is subject to a number of risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, the ability to obtain additional financing, protection of proprietary technology, dependence on key personnel, the ability to attract and retain qualified employees, compliance with government regulations, the impact of the COVID-19 pandemic and overall economic conditions, and the clinical and commercial success of its product candidates. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. Since inception, the Company has funded its operations primarily with payments received in connection with collaboration agreements, proceeds from equity and debt financing, and most recently, with proceeds from its 2020 initial public offering (“IPO”) and its 2021 follow-on offering (the "Follow-On Offering"), and an Open Market Sales Agreement (the "Sales Agreement"). On November 10, 2021, the Company entered into the Sales Agreement with Jefferies LLC (“Jefferies”) to issue and sell up to $ 75,000,000 in shares of the Company’s common stock from time to time during the term of the Sales Agreement through an “at-the-market” equity offering program under which Jefferies acts as the Company’s sales agent (the “ATM Facility”). The Company did no t sell any shares under the ATM Facility during both the three months ended March 31, 2023 and 2022. Going Concern Assessment Management has assessed the Company’s ability to continue as a going concern in accordance with the requirements of ASC 205-40, taking into consideration its recurring losses from operations incurred since inception, expectation of continuing operating losses for the foreseeable future and the need to raise additional capital to finance future operations. Through March 31, 2023, the Company has funded its operations primarily with proceeds from sales of convertible preferred stock, payments received in connection with collaboration agreements, proceeds from borrowings under a convertible promissory note, which converted into shares of convertible preferred stock, and more recently the proceeds from its IPO, the Follow-On Offering and the ATM Facility. The Company has incurred recurring losses since inception, including a net loss of $ 17.7 million for the three months ended March 31, 2023. As of March 31, 2023, the Company had an accumulated deficit of $ 292.7 million. Based on its current cash expenditure forecast, the Company expects that its existing cash and cash equivalents will fund its operations into the first quarter of 2024. The Company expects to continue to generate operating losses in the foreseeable future. As of May 10, 2023, the issuance date of the interim condensed consolidated financial statements for the three months ended March 31, 2023, the Company has concluded that there is substantial doubt about its ability to continue as a going concern for a period of one year from the date that these interim condensed consolidated financial statements are issued. The Company will require additional funding through private or public equity financings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. If the Company is unable to obtain funding, the Company will be forced to incur additional restructuring costs, delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, or at all. The accompanying interim condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. Accordingly, the interim condensed consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. Impact of Macroeconomic Conditions and the COVID-19 Pandemic The global economy, including credit and financial markets, has recently experienced extreme volatility and disruptions, including, for example, severely diminished liquidity and credit availability, rising interest and inflation rates, crises involving banking and financial institutions, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. In addition, the COVID-19 pandemic continues to be prevalent globally. The COVID-19 pandemic has impacted and may continue to impact personnel at third-party manufacturing facilities or the availability or cost of materials, which would disrupt the Company’s supply chain. Previously, it also has affected and may continue to affect the Company’s ability to enroll patients in and timely complete its ongoing clinical trials of SQZ-eAPC-HPV and SQZ-AAC-HPV and delay the initiation of future clinical trials, disrupt regulatory activities or have other adverse effects on its business and operations. The Company is monitoring the potential impact of general economic conditions and the COVID-19 pandemic on its business and financial statements. To date, the Company has not incurred impairment losses in the carrying values of its assets as a result of the pandemic and it is not aware of any specific related event or circumstance that would require it to revise its estimates reflected in these interim condensed consolidated financial statements. Unstable market and economic conditions and further disruption created by COVID-19 or other pandemics may have serious adverse consequences on the Company's business, financial condition and results of operations. Basis of Presentation The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying interim condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, SQZ Biotechnologies Security Corporation, SQZ Biotech HK Limited and SQZ Biotech (Shanghai) Co., Ltd . All intercompany accounts and transactions have been eliminated in consolidation.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Unaudited Interim Financial Information The accompanying condensed consolidated financial statements as of March 31, 2023 and for the three months ended March 31, 2023 and 2022 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. The accompanying condensed consolidated balance sheet as of December 31, 2022 was derived from audited financial statements but does not include all disclosures required by GAAP. Certain information and footnote disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These interim condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the SEC on March 22, 2023. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the Company’s consolidated financial position as of March 31, 2023, the consolidated results of operations for the three months ended March 31, 2023 and 2022, and the consolidated cash flows for the three months ended March 31, 2023 and 2022 have been made. The Company’s consolidated results of operations for the three months ended March 31, 2023 are not necessarily indicative of the results of operations that may be expected for the full year or any other subsequent interim period. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, revenue recognition, the accrual of research and development expenses, and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, judgments and methodologies as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions. Segment Information The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company is developing methods of engineering cell function and therapies for the treatment of patients across a range of indications. The Company has determined that its chief operating decision maker is its interim Chief Executive Officer. The Company’s chief operating decision maker reviews the Company’s financial information on a consolidated basis for purposes of allocating resources and assessing financial performance. Recently Issued Accounting Pronouncements The Company qualifies as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to “opt out” of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company will adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and will do so until such time that the Company either (i) irrevocably elects to “opt out” of such extended transition period or (ii) no longer qualifies as an emerging growth company. The Company may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for nonpublic companies.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	3. Fair Value Measurements The following tables present the Company’s fair value hierarchy for its assets and liabilities that are measured at fair value on a recurring basis (in thousands): FAIR VALUE MEASUREMENTS AT LEVEL 1 LEVEL 2 LEVEL 3 TOTAL Assets: Cash equivalents: Money market funds $ 37,212 $ — $ — $ 37,212 $ 37,212 $ — $ — $ 37,212 FAIR VALUE MEASUREMENTS AT LEVEL 1 LEVEL 2 LEVEL 3 TOTAL Assets: Cash equivalents: Money market funds $ 62,598 $ — $ — $ 62,598 $ 62,598 $ — $ — $ 62,598 Money market funds were valued by the Company based on quoted market prices, which represent a Level 1 measurement within the fair value hierarchy. There were no changes to the valuation methods during the three months ended March 31, 2023 .The Company evaluates transfers between levels at the end of each reporting period. There were no transfers between levels during the three months ended March 31, 2023 .

Property and Equipment, Net

Property and Equipment, Net	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	4. Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): MARCH 31, DECEMBER 31, 2023 2022 Machinery and equipment $ 6,905 $ 6,840 Leasehold improvements 579 579 Furniture and fixtures 319 319 $ 7,803 $ 7,738 Less: Accumulated depreciation and amortization ( 5,993 ) ( 5,779 ) $ 1,810 $ 1,959 Depreciation and amortization expense for the three months ended March 31, 2023 and 2022 was $ 0.2 million and $ 0.3 million, respectively.

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2023
Payables and Accruals [Abstract]
Accrued Expenses	5. Accrued Expenses Accrued expenses consisted of the following (in thousands): MARCH 31, DECEMBER 31, 2023 2022 Accrued external research, development and manufacturing costs $ 3,112 $ 5,264 Accrued employee compensation and benefits 807 2,578 Other 952 1,051 $ 4,871 $ 8,893

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	6. Stock-Based Compensation The following table summarizes the Company’s stock option activity since December 31, 2022: NUMBER OF WEIGHTED- WEIGHTED- INTRINSIC (in years) (in thousands) Outstanding at December 31, 2022 5,358,310 $ 8.09 5.26 $ — Granted 2,797,400 0.73 Forfeited or canceled ( 937,032 ) 7.75 Outstanding at March 31, 2023 7,218,678 $ 5.28 7.21 $ — Vested and expected to vest at March 31, 2023 7,218,678 $ 5.28 7.21 $ — Options exercisable at March 31, 2023 2,934,884 $ 8.35 4.04 $ — Stock-Based Compensation Expense Stock-based compensation expense related to stock options was classified in the consolidated statements of operations as follows (in thousands): THREE MONTHS ENDED 2023 2022 Research and development expenses $ 439 $ 655 General and administrative expenses 256 1,292 $ 695 $ 1,947 As of March 31, 2023 , total unrecognized stock-based compensation expense related to unvested stock-based awards was $ 8.5 million, which is expected to be recognized over a weighted-average period of 2.9 years.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	7. Income Taxes For the three months ended March 31, 2023 and 2022 , the Company recorded no income tax benefits for the net operating losses incurred or for the research and development tax credits generated in each period, due to its uncertainty of realizing a benefit from those items. Substantially all of the Company’s operating losses since inception have been generated in the United States.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies Leases The Company’s commitments under its leases are described in Note 9. License and Supply Agreements License Agreement with Massachusetts Institute of Technology In December 2015, the Company entered into an exclusive patent license agreement with the Massachusetts Institute of Technology (“MIT”) (the “MIT Agreement”). The MIT Agreement replaced a May 2013 exclusive agreement with MIT. Under the MIT Agreement, the Company received an exclusive license under the licensed patent rights to develop, manufacture and commercialize any products related to certain intracellular delivery methods that were developed at MIT. As of March 31, 2023 and December 31, 2022 , the Company had no outstanding liabilities related to the MIT Agreement. During each of the three months ended March 31, 2023 and 2022 , the Company recognized less than $ 0.1 million in research and development expense under the sublicense terms of the MIT Agreement. Manufacturing Services Agreements The Company has entered into agreements with contract manufacturing organizations to provide manufacturing services related to its product candidates. As of March 31, 2023, the Company had no non-cancelable payments under these agreements, as amended, other than the amounts included in the current portion of operating lease liabilities on the Company's consolidated balance sheets. 401(k) Plan The Company sponsors a 401(k) defined contribution benefit plan (the “401(k) Plan”), which covers all employees who meet certain eligibility requirements as defined in the 401(k) Plan and allows participants to defer a portion of their annual compensation on a pre-tax basis. Contributions to the 401(k) Plan may be made at the discretion of management. For each of the three months ended March 31, 2023 and 2022 , the Company contributed $ 0.1 million to the 401(k) Plan. Indemnification Agreements In the ordinary course of business, the Company may provide indemnification of varying scope and terms to its vendors, lessors, contract research organizations, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with its executive officers and members of its board of directors that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or executive officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnification agreements and is not currently aware of any indemnification claims. Legal Proceedings The Company is not currently party to any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.

Leases

Leases	3 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Leases	9. Leases As of March 31, 2023, the Company leases its office and laboratory facilities under a non-cancelable operating lease entered into in December 2018, which included lease incentives, payment escalations and rent holidays. In addition, the Company has an agreement entered into in April 2019 with a contract manufacturing supplier that is considered an embedded lease because the Company has substantially all the economic benefits of the related asset and can direct its use. The Company had not entered into any financing leases or any short-term operating leases as of March 31, 2023 and December 31, 2022. The components of lease cost were as follows (in thousands): THREE MONTHS ENDED 2023 2022 Lease cost: Operating lease cost $ 3,359 $ 3,760 Variable lease cost 410 557 $ 3,769 $ 4,317

License and Collaboration Agree

License and Collaboration Agreements	3 Months Ended
	Mar. 31, 2023
Research and Development [Abstract]
License and Collaboration Agreements	10. License and Collaboration Agreements 2018 License and Collaboration Agreement with Roche In October 2018, the Company entered into a license and collaboration agreement with Roche (the “2018 Roche Agreement”) to jointly develop certain products based on mononuclear antigen presenting cells (“APCs”), including human papillomavirus (“HPV”), using the SQZ APC platform for the treatment of oncology indications. The Company granted Roche a non-exclusive license to its intellectual property, and Roche granted the Company a non-exclusive license to its and its affiliates’ intellectual property for the purpose of performing research activities. In connection with this agreement, the parties terminated an earlier agreement. The 2018 Roche Agreement has a term that extends until all royalty, profit-share and other payment obligations expire or have been satisfied. Roche has the right to terminate the 2018 Roche Agreement, in whole or on a product-by-product basis, upon a specified amount of notice to the Company. The Company or Roche may terminate the agreement if the other party fails to cure its material breach within a specified period after receiving notice of such breach. Under the 2018 Roche Agreement, Roche was granted option rights to obtain an exclusive license to develop APC products or products derived from the collaboration programs on a product-by-product basis. These option rights are exercisable upon the achievement of clinical Phase 1 proof of concept and expire, if unexercised, as of a date specified in the agreement. In addition, Roche was granted an option right to obtain an exclusive license to develop a Tumor Cell Lysate (“TCL”) product. This option right is exercisable upon the achievement of clinical proof of concept and expires, if unexercised, as of a date specified in the agreement. For each of the APC products and TCL product, once Roche exercises its option and pays a specified incremental amount ranging from $ 15.0 million to $ 50.0 million for APC products and of $ 100.0 million for the TCL product, Roche will receive worldwide, exclusive commercialization rights for the licensed products, subject to the Company’s alternating option to retain U.S. APC commercialization rights. The Company will retain worldwide commercialization rights to any APC products or the TCL product for which Roche elects not to exercise its applicable option. For the first APC product that Roche exercises its option, Roche will receive worldwide, exclusive commercialization rights for the licensed product. On a product-by-product basis for the APC products, after the first product option is exercised by Roche and for every other product for which Roche exercises its option, the Company will retain an option to obtain the exclusive commercialization rights in the United States. Upon exercise of the TCL option by Roche, (i) the Company will be entitled to receive the aforementioned milestone payment of $ 100.0 million and (ii) profits from the TCL product will be shared equally by the Company and Roche. Through March 31, 2023, Roche had not exercised any of its options under the 2018 Roche Agreement. Under the 2018 Roche Agreement, the Company received an upfront payment of $ 45.0 million and is eligible to receive (i) reimbursement of a mid-double-digit percentage of its development costs; (ii) aggregate milestone payments on a product-by-product basis of up to $ 1.6 billion upon the achievement of specified milestones, consisting of up to $ 217.0 million of development milestone payments, up to $ 240.0 million of regulatory milestone payments and up to $ 1.2 billion of sales milestone payments; and (iii) tiered royalties on annual net sales of APC and TCL products licensed under the agreement, as described below. The Company received the upfront payment of $ 45.0 million in October 2018 upon execution of the agreement. In addition, during the second quarter of 2019, the Company received a payment of $ 10.0 million following the achievement of the first development milestone under the 2018 Roche Agreement related to submission by the Company of preclinical data to the U.S. Food and Drug Administration (“FDA”). During the first quarter of 2020, the Company received a payment of $ 20.0 million following the achievement of the second development milestone under the 2018 Roche Agreement related to first-patient dosing in a Phase 1 clinical trial. In the first quarter of 2022, the Company received a milestone payment of $ 3.0 million having achieved in the fourth quarter of 2021 the following: (i) the endorsement by an independent panel that it could advance its SQZ-PBMC-HPV clinical trial to combination therapy using checkpoint inhibitors and (ii) the initiation of that therapy. Roche will pay tiered royalties based on annual net sales of APC and TCL products. If Roche exercises its option to obtain a license to commercialize an APC product, Roche will pay the Company tiered royalties on annual net sales of that licensed product at rates ranging from a mid-single-digit percentage to a mid-teens percentage, depending on net sales of the product. If the Company exercises its option to obtain a license to commercialize an APC product in the United States, it will pay Roche tiered royalties on annual net sales of that licensed product at rates ranging from a mid-single-digit percentage to a mid-teens percentage, depending on net sales of the product in the United States. For APC products selected by Roche, rather than mutually, Roche will pay the Company royalties on annual net sales of that licensed product at rates ranging from a mid-single-digit percentage to a high single-digit percentage, depending on net sales of the product. For APC products that are selected mutually and for which the Company has not exercised its option to commercialize the product in the United States, Roche will pay the Company tiered royalties on annual net sales of that licensed product at a rate ranging from a high single-digit percentage to a mid-teens percentage, depending on net sales of the product. For TCL products, Roche will pay the Company tiered royalties on the aggregate net sales of all TCL products at rates ranging from either a mid-single digit percentage to a percentage in the low twenties, with the caveat that the rates for sales in the United States may instead range from a low-teens percentage to a percentage in the mid-twenties, depending on whether and when the Company opts out of sharing certain profits and costs of commercializing the TCL product in the United States with Roche. The Company identified three performance obligations at the outset of the 2018 Roche Agreement: (1) the license to the Company’s intellectual property, the research and development activities related to HPV through Phase 1 clinical trials under a specified research plan, and the manufacturing of the Company’s SQZ APC platform and equipment in order to support the HPV research plan (the “first performance obligation”); (2) the license to the Company’s intellectual property and the research and development activities on next-generation APCs (the “second performance obligation”); and (3) the license to the Company’s intellectual property and the research and development activities on TCL (the “third performance obligation”). The Company separately recognizes revenue associated with each of the three performance obligations as the research, development and manufacturing services are provided using an input method, based on the cumulative costs incurred compared to the total estimated costs expected to be incurred to satisfy each performance obligation. The transfer of control to the customer occurs over the time period that the research and development services are to be provided by the Company, and this cost-to-cost method is, in management’s judgment, the best measure of progress towards satisfying each performance obligation. The amounts received that have not yet been recognized as revenue are deferred as a contract liability in the Company’s consolidated balance sheet and will be recognized over the remaining research and development period until each performance obligation is satisfied. During the three months ended March 31, 2023 and 2022 , there were no significant changes in the total estimated costs expected to be incurred to satisfy the performance obligations under the 2018 Roche Agreement. The Company recognized no revenue and $ 2.9 million during the three months ended March 31, 2023 and 2022, respectively, under this agreement. As of March 31, 2023, the Company recorded as a contract liability deferred revenue related to the 2018 Roche Agreement of $ 0.1 million, all of which was a current liability. As of March 31, 2023 , the research and development services related to the performance obligations were expected to be performed over a remaining period of three months . Contract Liability The changes in the total contract liability (deferred revenue) balances related to the Company’s license and collaboration agreements were as follows (in thousands): THREE MONTHS ENDED 2023 2022 Balance at beginning of period $ 174 $ 21,203 Recognition of deferred revenue — ( 2,869 ) Balance at end of period $ 174 $ 18,334

Net Loss per Share

Net Loss per Share	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Net Loss per Share	11. Net Loss per Share Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts): THREE MONTHS ENDED 2023 2022 Numerator: Net loss $ ( 17,687 ) $ ( 21,038 ) Denominator: Weighted-average common shares outstanding, basic and 29,491,125 28,145,036 Net loss per share attributable to common stockholders, basic and $ ( 0.60 ) $ ( 0.75 ) The Company’s potential dilutive securities, which consist of common stock options have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: THREE MONTHS ENDED 2023 2022 Stock options to purchase common stock 7,218,678 6,091,427 7,218,678 6,091,427

Restructuring

Restructuring	3 Months Ended
	Mar. 31, 2023
Restructuring and Related Activities [Abstract]
Restructuring	12. Restructuring On November 30, 2022, the Company’s Board of Directors approved a restructuring plan and strategic prioritization (the “Restructuring”) of its clinical portfolio to concentrate on the development of its second-generation enhanced Antigen Presenting Cells (eAPC) cell therapy program. In connection with the Restructuring, the Company reprioritized its clinical and development programs, determined to terminate operations in its Hong Kong and China subsidiaries and the Board of Directors approved a workforce reduction of approximately 60 %, including research and development and general and administrative support functions in the United States and China. In the first quarter of 2023, the Company decided to continue to enroll patients in its SQZ-AAC-HPV clinical trial. The following table summarizes the activity for accrued restructuring costs for the three months ended March 31, 2023 (in thousands): Employee Related Costs Facility Related Costs Total Balance as of December 31, 2022 $ 3,162 $ — $ 3,162 Expenses incurred ( 7 ) — ( 7 ) Payments ( 2,618 ) ( 69 ) ( 2,687 ) Balance as of March 31, 2023 $ 537 $ ( 69 ) $ 468 During the three months ended March 31, 2023, the Company recorded a net reduction of $ 7 thousand of restructuring charges based on a revised estimate of remaining employee related restructuring costs. The accrued restructuring liability of $ 0.5 million is payable within the next twelve months and has been included as accrued restructuring costs in current liabilities in the consolidated balance sheet. The remaining accrued restructuring charges are subject to assumptions, and actual amounts may differ. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the Restructuring.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Unaudited Interim Financial Information	Unaudited Interim Financial Information The accompanying condensed consolidated financial statements as of March 31, 2023 and for the three months ended March 31, 2023 and 2022 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. The accompanying condensed consolidated balance sheet as of December 31, 2022 was derived from audited financial statements but does not include all disclosures required by GAAP. Certain information and footnote disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These interim condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the SEC on March 22, 2023. In the opinion of management, all adjustments, consisting only of normal recurring adjustments necessary for a fair statement of the Company’s consolidated financial position as of March 31, 2023, the consolidated results of operations for the three months ended March 31, 2023 and 2022, and the consolidated cash flows for the three months ended March 31, 2023 and 2022 have been made. The Company’s consolidated results of operations for the three months ended March 31, 2023 are not necessarily indicative of the results of operations that may be expected for the full year or any other subsequent interim period.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, revenue recognition, the accrual of research and development expenses, and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, judgments and methodologies as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions.
Segment Information	Segment Information The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company is developing methods of engineering cell function and therapies for the treatment of patients across a range of indications. The Company has determined that its chief operating decision maker is its interim Chief Executive Officer. The Company’s chief operating decision maker reviews the Company’s financial information on a consolidated basis for purposes of allocating resources and assessing financial performance.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements The Company qualifies as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to “opt out” of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company will adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and will do so until such time that the Company either (i) irrevocably elects to “opt out” of such extended transition period or (ii) no longer qualifies as an emerging growth company. The Company may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for nonpublic companies.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Summary of fair value hierarchy for assets and liabilities	The following tables present the Company’s fair value hierarchy for its assets and liabilities that are measured at fair value on a recurring basis (in thousands): FAIR VALUE MEASUREMENTS AT LEVEL 1 LEVEL 2 LEVEL 3 TOTAL Assets: Cash equivalents: Money market funds $ 37,212 $ — $ — $ 37,212 $ 37,212 $ — $ — $ 37,212 FAIR VALUE MEASUREMENTS AT LEVEL 1 LEVEL 2 LEVEL 3 TOTAL Assets: Cash equivalents: Money market funds $ 62,598 $ — $ — $ 62,598 $ 62,598 $ — $ — $ 62,598

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment, Net [Abstract]
Summary of property and equipment, net	Property and equipment, net consisted of the following (in thousands): MARCH 31, DECEMBER 31, 2023 2022 Machinery and equipment $ 6,905 $ 6,840 Leasehold improvements 579 579 Furniture and fixtures 319 319 $ 7,803 $ 7,738 Less: Accumulated depreciation and amortization ( 5,993 ) ( 5,779 ) $ 1,810 $ 1,959

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2023
Payables and Accruals [Abstract]
Summary of accrued expenses	Accrued expenses consisted of the following (in thousands): MARCH 31, DECEMBER 31, 2023 2022 Accrued external research, development and manufacturing costs $ 3,112 $ 5,264 Accrued employee compensation and benefits 807 2,578 Other 952 1,051 $ 4,871 $ 8,893

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Summary of Stock Option Activity	The following table summarizes the Company’s stock option activity since December 31, 2022: NUMBER OF WEIGHTED- WEIGHTED- INTRINSIC (in years) (in thousands) Outstanding at December 31, 2022 5,358,310 $ 8.09 5.26 $ — Granted 2,797,400 0.73 Forfeited or canceled ( 937,032 ) 7.75 Outstanding at March 31, 2023 7,218,678 $ 5.28 7.21 $ — Vested and expected to vest at March 31, 2023 7,218,678 $ 5.28 7.21 $ — Options exercisable at March 31, 2023 2,934,884 $ 8.35 4.04 $ —
Summary of Stock-Based Compensation Expense	Stock-based compensation expense related to stock options was classified in the consolidated statements of operations as follows (in thousands): THREE MONTHS ENDED 2023 2022 Research and development expenses $ 439 $ 655 General and administrative expenses 256 1,292 $ 695 $ 1,947

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Summary of Components of Lease Cost	The components of lease cost were as follows (in thousands): THREE MONTHS ENDED 2023 2022 Lease cost: Operating lease cost $ 3,359 $ 3,760 Variable lease cost 410 557 $ 3,769 $ 4,317

License and Collaboration Agr_2

License and Collaboration Agreements (Tables)	3 Months Ended
	Mar. 31, 2023
Research and Development [Abstract]
Summary of Changes in the Total Contract Liability	The changes in the total contract liability (deferred revenue) balances related to the Company’s license and collaboration agreements were as follows (in thousands): THREE MONTHS ENDED 2023 2022 Balance at beginning of period $ 174 $ 21,203 Recognition of deferred revenue — ( 2,869 ) Balance at end of period $ 174 $ 18,334

Net Loss per Share (Tables)

Net Loss per Share (Tables)	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Summary of basic and diluted net loss per share attributable to common stockholders	Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts): THREE MONTHS ENDED 2023 2022 Numerator: Net loss $ ( 17,687 ) $ ( 21,038 ) Denominator: Weighted-average common shares outstanding, basic and 29,491,125 28,145,036 Net loss per share attributable to common stockholders, basic and $ ( 0.60 ) $ ( 0.75 )
Summary of potentially dilutive shares excluded from the calculation of diluted net loss	The Company’s potential dilutive securities, which consist of common stock options have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: THREE MONTHS ENDED 2023 2022 Stock options to purchase common stock 7,218,678 6,091,427 7,218,678 6,091,427

Restructuring (Tables)

Restructuring (Tables)	3 Months Ended
	Mar. 31, 2023
Restructuring and Related Activities [Abstract]
Summary of Accrued Restructuring Costs	The following table summarizes the activity for accrued restructuring costs for the three months ended March 31, 2023 (in thousands): Employee Related Costs Facility Related Costs Total Balance as of December 31, 2022 $ 3,162 $ — $ 3,162 Expenses incurred ( 7 ) — ( 7 ) Payments ( 2,618 ) ( 69 ) ( 2,687 ) Balance as of March 31, 2023 $ 537 $ ( 69 ) $ 468

Nature of the Business and Ba_2

Nature of the Business and Basis of Presentation - Additional Information (Detail) - USD ($)		3 Months Ended
	Nov. 10, 2021	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Number of shares sold at-the-market offering facility		0	0
Income (loss) from continuing operations		$ 17,700,000
Accumulated deficit		$ 292,661,000		$ 274,974,000
Follow-on Offering [Member] | Maximum [Member]
Proceeds from issuance of common stock under at-the market offering	$ 75,000,000

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Fair Value Hierarchy for Assets and Liabilities (Detail) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Assets:
Assets, fair value disclosure	$ 37,212	$ 62,598
Level 1 [Member]
Assets:
Assets, fair value disclosure	37,212	62,598
Money Market Funds [Member] | Cash equivalents [Member]
Assets:
Assets, fair value disclosure	37,212	62,598
Money Market Funds [Member] | Cash equivalents [Member] | Level 1 [Member]
Assets:
Assets, fair value disclosure	$ 37,212	$ 62,598

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details)	Mar. 31, 2023 USD ($)
Fair Value Disclosures [Abstract]
Fair value, assets, level 1 to level 2 transfers, amount	$ 0
Fair value, assets, level 2 to level 1 transfers, amount	0
Fair value, liabilities, level 1 to level 2 transfers, amount	0
Fair value, liabilities, level 2 to level 1 transfers, amount	0
Fair value, assets, level 1 to level 3 transfers, amount	0
Fair value, assets, level 2 to level 3 transfers, amount	0
Fair value, assets, level 3 to level 1 transfers, amount	0
Fair value, assets, level 3 to level 2 transfers, amount	0
Fair value, liabilities, level 1 to level 3 transfers, amount	0
Fair value, liabilities, level 2 to level 3 transfers, amount	0
Fair value, liabilities, level 3 to level 1 transfers, amount	0
Fair value, liabilities, level 3 to level 2 transfers, amount	$ 0

Property and Equipment, Net - S

Property and Equipment, Net - Summary of Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment, Net [Abstract]
Machinery and equipment	$ 6,905	$ 6,840
Leasehold improvements	579	579
Furniture and fixtures	319	319
Total property and equipment, gross	7,803	7,738
Less: Accumulated depreciation and amortization	(5,993)	(5,779)
Total property and equipment, net	$ 1,810	$ 1,959

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Property, Plant and Equipment [Line Items]
Depreciation and amortization expense	$ 214	$ 276

Accrued Expenses - Summary of A

Accrued Expenses - Summary of Accrued Expenses (Detail) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Accrued external research, development and manufacturing costs	$ 3,112	$ 5,264
Accrued employee compensation and benefits	807	2,578
Other	952	1,051
Total accrued expenses	$ 4,871	$ 8,893

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Detail) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Number Of Shares - Outstanding at December 31, 2022	5,358,310
Granted	2,797,400
Forfeited or canceled	(937,032)
Number Of Shares - Outstanding at March 31, 2023	7,218,678	5,358,310
Number Of Shares - Vested and expected to vest at March 31, 2023	7,218,678
Number Of Shares - Options exercisable at March 31, 2023	2,934,884
Weighted Average Exercise Price - Outstanding at December 31, 2022	$ 8.09
Granted	0.73
Forfeited or canceled	7.75
Weighted Average Exercise Price - Outstanding at March 31, 2023	5.28	$ 8.09
Weighted Average Exercise Price - Vested and expected to vest at March 31, 2023	5.28
Weighted Average Exercise Price - Options exercisable at March 31, 2023	$ 8.35
Weighted-Average Remaining Contractual Term	7 years 2 months 15 days	5 years 3 months 3 days
Weighted-Average Remaining Contractual Term - Vested and expected to vest	7 years 2 months 15 days
Weighted-Average Remaining Contractual Term - Options exercisable	4 years 14 days

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 695	$ 1,947
Research and Development Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	439	655
General and Administrative Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 256	$ 1,292

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($)
Stockbased Compensation [Line Items]
Unrecognized compensation expense related to unvested stock based awards	$ 8.5
Unrecognized compensation expense expected period for recognition	2 years 10 months 24 days

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income tax benefits	$ 0	$ 0

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Other Commitments [Line Items]
Commitments and contingencies (Note 8)
Research and development	12,976,000	$ 17,010,000
Discretionary contribution by the employer to defined contribution benefit plan	100,000	100,000
Manufacturing Services Agreements [Member]
Other Commitments [Line Items]
Non-cancelable payments	0
Sublicense Agreement [Member] | Maximum [Member]
Other Commitments [Line Items]
Research and development	100,000	$ 100,000
Massachusetts Institute Of Technology
Other Commitments [Line Items]
Commitments and contingencies (Note 8)	$ 0		$ 0

Leases - Summary of Components

Leases - Summary of Components of Lease Cost (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Lease cost:
Operating lease cost	$ 3,359	$ 3,760
Variable lease cost	410	557
Lease Cost	$ 3,769	$ 4,317

License and Collaboration Agr_3

License and Collaboration Agreements - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended
	Oct. 31, 2018	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2020	Jun. 30, 2019	Dec. 31, 2022	Dec. 31, 2021
License And Collaboration Agreements [Line Items]
Contract with customer liability revenue recognized			$ 2,869,000
Contract with customer liability		$ 174,000	18,334,000			$ 174,000	$ 21,203,000
2018 License and Collaboration Agreement With Roche [Member]
License And Collaboration Agreements [Line Items]
Milestone payment receivable on exercise of option rights		100,000,000
2018 License and Collaboration Agreement With Roche [Member] | Roche [Member]
License And Collaboration Agreements [Line Items]
Upfront payment received towards technology access fee	$ 45,000,000
Estimated costs to be incurred to satisfy performance obligation		0	0
Milestone payment receivable based on product		1,600,000
Milestone payment received			3,000
Performance obligation revenue recognized		0	2,900,000
Estimated Costs To Be Incurred To Satisfy Performance Obligation		0	$ 0
Contract with customer liability		100,000
2018 License and Collaboration Agreement With Roche [Member] | Roche [Member] | Development Milestone [Member]
License And Collaboration Agreements [Line Items]
Milestone payment receivable based on product		217,000,000
2018 License and Collaboration Agreement With Roche [Member] | Roche [Member] | Development Milestone [Member] | First Patient Doosing Phase One Clinical Trial [Member]
License And Collaboration Agreements [Line Items]
Milestone payment received				$ 20,000,000
2018 License and Collaboration Agreement With Roche [Member] | Roche [Member] | Regulatory Milestone [Member]
License And Collaboration Agreements [Line Items]
Milestone payment receivable based on product		240,000,000
2018 License and Collaboration Agreement With Roche [Member] | Roche [Member] | Regulatory Milestone [Member] | Preclinical Data Submitted To FDA For Approval [Member]
License And Collaboration Agreements [Line Items]
Milestone payment received					$ 10,000,000
2018 License and Collaboration Agreement With Roche [Member] | Roche [Member] | Sales Milestone [Member]
License And Collaboration Agreements [Line Items]
Milestone payment receivable based on product		1,200,000,000
2018 License and Collaboration Agreement With Roche [Member] | Roche [Member] | APC [Member]
License And Collaboration Agreements [Line Items]
Amount payable on exercise of option rights to use the license		15,000,000
2018 License and Collaboration Agreement With Roche [Member] | Roche [Member] | Maximum [Member] | TCL [Member]
License And Collaboration Agreements [Line Items]
Amount payable on exercise of option rights to use the license		100,000,000
2018 License and Collaboration Agreement With Roche [Member] | Roche [Member] | Minimum [Member] | TCL [Member]
License And Collaboration Agreements [Line Items]
Amount payable on exercise of option rights to use the license		$ 50,000,000

License and Collaboration Agr_4

License and Collaboration Agreements - Additional Information (Detail1)	Mar. 31, 2023
2018 License and Collaboration Agreement With Roche [Member] | Roche [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-10-01
License And Collaboration Agreements [Line Items]
Remaining period over which the performance obligation is to be satisfied	3 months

License and Collaboration Agr_5

License and Collaboration Agreements - Summary of Changes in the Total Contract Liability (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2022 USD ($)
Research and Development [Abstract]
Balance at beginning of period	$ 21,203
Recognition of deferred revenue	(2,869)
Balance at end of period	$ 18,334

Net Loss Per Share - Summary of

Net Loss Per Share - Summary of basic and diluted net loss per share attributable to common stockholders (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Earnings Per Share [Abstract]
Net loss	$ (17,687)	$ (21,038)
Weighted-average common shares outstanding, basic	29,491,125	28,145,036
Weighted-average common shares outstanding, diluted	29,491,125	28,145,036
Net loss per share attributable to common stockholders, basic	$ (0.60)	$ (0.75)
Net loss per share attributable to common stockholders, diluted	$ (0.60)	$ (0.75)

Net Loss Per Share - Summary _2

Net Loss Per Share - Summary of potentially dilutive shares excluded from the calculation of diluted net loss (Detail) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	7,218,678	6,091,427
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	7,218,678	6,091,427

Restructuring - Additional Info

Restructuring - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Nov. 30, 2022	Mar. 31, 2023	Dec. 31, 2022
Restructuring Cost and Reserve [Line Items]
Percentage of reduction in workforce	60%
Restructuring charges		$ (7)
Accrued restructuring liability		468	$ 3,162
Employee Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges		$ (7)

Restructuring - Summary of Accr

Restructuring - Summary of Accrued Restructuring Costs (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Beginning Balance	$ 3,162
Expenses incurred	(7)
Payments	(2,687)
Restructuring Reserve, Ending Balance	468
Employee Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Beginning Balance	3,162
Expenses incurred	(7)
Payments	(2,618)
Restructuring Reserve, Ending Balance	537
Facility Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Payments	(69)
Restructuring Reserve, Ending Balance	$ (69)